Setipiprant
As of the edition of 20 October 2026, Setipiprant is a small molecule: went quiet in 2018; acts on PTGDR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2018
- Kind
- Small molecule
- Registered trials
- 5, 0 stopped early
- Disease areas
- Immune system; Lungs and airways; Ear, nose and throat; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Setipiprant.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTGDR2 | Prostaglandin D2 receptor 2 | Q9Y5Y4 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 3 | 3 | 0 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Idorsia Pharmaceuticals | Lead sponsor of trials | 2010 to now |
| AbbVie | Lead sponsor of trials | 2016 to now |